TargImmune Therapeutics
TargImmune is dedicated to transforming survival for cancer patients through its innovative portfolio of oncology compounds and groundbreaking modular, synthetic, targeted platform technology. Their proprietary Ta:RNA™ platform harnesses the body's immune system to target and destroy cancer cells, offering a multi-pronged approach against solid tumours and metastases. The company aims to significantly improve patient outcomes by developing targeted immunotherapies that can be delivered systemically, reaching distant metastases and addressing a wide range of cancers.
Industries
Nr. of Employees
small (1-50)
TargImmune Therapeutics
Hochbergerstrasse 60C, 4057 Basel, Switzerland
Patents
Systems and methods for automatically generating a data center network mapping for automated alarm consolidation
US-11743104-B2
View Details
Systems and methods for automatically generating a data center network mapping for automated alarm consolidation
US-11743104-B2
View DetailsProducts
TAR001
Lead platform-derived clinical candidate that targets tumour cells via an overexpressed receptor to deliver synthetic double-stranded RNA systemically, designed to induce tumour cell death and immune modulation.
TAR002
Second platform-derived nucleic acid therapeutic currently in preclinical development, representing an additional receptor-targeted TAIM-class candidate.
TAR001
Lead platform-derived clinical candidate that targets tumour cells via an overexpressed receptor to deliver synthetic double-stranded RNA systemically, designed to induce tumour cell death and immune modulation.
TAR002
Second platform-derived nucleic acid therapeutic currently in preclinical development, representing an additional receptor-targeted TAIM-class candidate.
Expertise Areas
- Targeted nucleic acid therapeutics
- Oncology drug development (solid tumours)
- Nanoparticle-mediated targeted delivery
- Preclinical GLP toxicology and safety assessment
Key Technologies
- Synthetic nanoparticle delivery
- Double-stranded RNA therapeutics (dsRNA)
- Receptor-targeted ligand/moiety exchange (modular targeting)
- Systemic nucleic acid delivery
News & Updates
TargImmune raised CHF 17.7 million in its 2021 financing round and appointed Peter Braun as CEO, effective August 16, 2021. The company is progressing towards filing an IND with the FDA and starting clinical programs.
Christoph Rentsch, a co-founder of TargImmune, was appointed full-time CFO. He has extensive experience in private and public funding markets and has served in executive roles in biotech companies.
Learn more about how TargImmune is harnessing antiviral defenses in cancer therapy, as featured in Nature Biopharma Dealmakers.
The company announced the successful completion of GLP/Tox studies and the appointment of Dr. Marc Thommen as Head of Technical Development.
TargImmune announced the appointment of Veronica Hersberger as Chief Medical Officer, expanding their management team.
TargImmune raised CHF 17.7 million in its 2021 financing round and appointed Peter Braun as CEO, effective August 16, 2021. The company is progressing towards filing an IND with the FDA and starting clinical programs.
Christoph Rentsch, a co-founder of TargImmune, was appointed full-time CFO. He has extensive experience in private and public funding markets and has served in executive roles in biotech companies.
Learn more about how TargImmune is harnessing antiviral defenses in cancer therapy, as featured in Nature Biopharma Dealmakers.
The company announced the successful completion of GLP/Tox studies and the appointment of Dr. Marc Thommen as Head of Technical Development.
TargImmune announced the appointment of Veronica Hersberger as Chief Medical Officer, expanding their management team.